I. Nkhana

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

P. Easterbrook, H. Namata, A. Siika, 2018, The Lancet. Infectious diseases.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

P. Easterbrook, T. Peto, N. French, 2017, The lancet. HIV.

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial

P. Easterbrook, N. French, H. Namata, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.